Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa

EClinicalMedicine(2020)10.1016/j.eclinm.2020.100313Source: DataRank Database

A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa is a research paper published in EClinicalMedicine (2020). On theSindex it has a DataRank of 2.3. It has been cited 75 times, with 66 citing works in its 1-hop citation network.

N/A

2.3DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access75 citations · 66 citing works in its network

Free full text

Cite:

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02378207

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 1.14)OA: goldTopics (18)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 28%Citation Network 72%

Base Score Contribution

0.650

From this paper's citation signal

Citation Network Contribution

1.6

From 62 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 66 citers.

Evaluating H56:IC31 vaccine in tuberculosis recurrence prevention
The Lancet Infectious Diseases20253 citations9 referencesContributes 0.154
Safety and Immunogenicity of the GamTBvac, the Recombinant Subunit Tuberculosis Vaccine Candidate: A Phase II, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study
Vaccines202073 citations30 referencesContributes 0.143
The Case for Why Africa Should Host COVID-19 Candidate Vaccine Trials
The Journal of Infectious Diseases202018 citations23 referencesContributes 0.128
Guinea Pig Model of Mycobacterium tuberculosis Infection
Current Protocols202110 citations19 referencesContributes 0.126
Revisiting the Chingleput BCG vaccination trial for the impact of BCG revaccination on the incidence of tuberculosis disease
International Journal of Microbiology Research202223 citations27 referencesContributes 0.118

Authors (21)

One Dintwe ORCID,Andrew Fioré-Gartland ORCID,Keren Middelkoop ORCID,Julia Hütter ORCID,Anthony Williams

Live enrichment

PubMed:32382714 OpenAlex:https://openalex.org/W3011610724

U.S. Public Health Service

Grant: UM1 AI069519

U.S. Public Health Service

Grant: UM1 AI068635

U.S. Public Health Service

Grant: UM1 AI068618

U.S. Public Health Service

Grant: UM1 AI068614

National Institutes of Health

Grant: P30 AI064518

National Institutes of Health

Grant: 3UM1AI068635-17S4

CoVPN 3001 - A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults.

National Institutes of Health

Grant: 3UM1AI068614-15S2

CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older

National Institutes of Health

Grant: 5P30AI064518-17

Centers for AIDS Research (CFAR)

National Institutes of Health

Grant: 5UM1AI069519-16

HIV/AIDS Clinical Trials Units University of Cape Town CTU 2020 to 2027

National Institutes of Health

Grant: 3UM1AI068618-16S1

HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals: LC 3

FWCI

1.14

Citation Percentile

0.9%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttp://www.thelancet.com/article/S2589537020300572/pdf

publisherhttp://www.thelancet.com/article/S2589537020300572/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2589537020300572?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2589537020300572?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.eclinm.2020.100313

Fields of Study

Tuberculosis Research and EpidemiologyImmunodeficiency and Autoimmune DisordersImmune responses and vaccinations0301 basic medicine03 medical and health sciences

Keywords

MedicineImmunogenicityVaccinationImmunologyTuberculosisMycobacterium tuberculosisAntigenAntibodyTuberculosis vaccinesPathologyMedicine (General)R5-920Research paper

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being